Development of Cancer Immunoprevention in a High-Risk Population of Canadian Inuits: Characterization of Frame-Shift Neoantigen Expression in Homozygous Individuals and Carriers of PMS2 Mutations

NIH RePORTER · NIH · N01 · $24,717 · view on reporter.nih.gov ↗

Abstract

Project hypothesizes that the recurrent frame-shift mutations observed in Lynch Syndrome will also occur in CMMRD Syndrome and that the neoantigen vaccine strategy and reagents will be directly relevant to cancer prevention in CMMRD Syndrome.

Key facts

NIH application ID
10725425
Project number
75N91019D00024-P00018-759102000003-56
Recipient
LEIDOS BIOMEDICAL RESEARCH, INC.
Principal Investigator
LEONARD FREEDMAN
Activity code
N01
Funding institute
NIH
Fiscal year
2022
Award amount
$24,717
Award type
—
Project period
2020-08-31 → 2022-08-30